logo

For the Inventor, By the Inventor

Palo Alto, CA, United States of America

Ying Liu

This inventor holds 11 USPTO granted patents and 11 published patent applications and 4 EPO patents. Top assignees: Amgen Fremont Inc., Microsoft Technology Licensing, LLC. Active years: 2009-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ying Liu. Retrieved from https://idiyas.com/inventor/ying-liu-m9jszi9j

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 100.0

 

Average Co-Inventor Count = 10.7

ph-index = 4

Forward Citations = 124(Granted Patents)


Company Filing History:

goldMedal9 out of 78 
 
Amgen Fremont Inc.
 patents
silverMedal2 out of 56,279 
 
Microsoft Technology Licensing, LLC
 patents

Years Active: 2009-2022

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 11492411 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2022-11-08),
2. 10508153 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2019-12-17),
3. 10382577 - Trending topics on a social network based on member profiles (2019-08-13),
4. 10118968 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2018-11-06),
5. 9882785 - Social network content spread visualization (2018-01-30),
6. 9096672 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-08-04),
7. 9085624 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-07-21),
8. 9073998 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-07-07),
9. 9062113 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2015-06-23),
10. 7736644 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2010-06-15),
11. 7628986 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof (2009-12-08),

Title: Ying Liu: Innovator in Antibody Development

Introduction

Ying Liu is a prominent inventor based in Palo Alto, California, known for his significant contributions to the field of biotechnology. With a total of 11 patents to his name, Liu has focused on developing novel antibodies that target specific deletion mutants of the epidermal growth factor receptor.

Latest Patents

One of Liu's latest patents is centered around antibodies directed to the deletion mutants of the epidermal growth factor receptor, particularly the type III deletion mutant known as EGFRvIII. This invention encompasses human monoclonal antibodies that are specifically designed to target these deletion mutants. Additionally, the patent includes diagnostic and therapeutic formulations of such antibodies, as well as immunoconjugates derived from them.

Career Highlights

Throughout his career, Ying Liu has worked with notable companies such as Amgen Fremont Inc. and Microsoft Technology Licensing, LLC. His work in these organizations has contributed to advancements in biotechnology and therapeutic development.

Collaborations

Liu has collaborated with esteemed colleagues, including Richard F. Weber and Xiao Feng, further enhancing the impact of his research and innovations.

Conclusion

Ying Liu's work in antibody development has positioned him as a key figure in biotechnology, with a focus on innovative solutions for targeting specific cancer-related mutations. His contributions continue to influence the field and pave the way for future advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…